Sun Pharmaceutical Industries Limited

rs,

mited to, express or implied: • • • • • statements regarding the transaction and related matters, including the benefits of and timeline for closing the transaction, prospective performance and oppo

20%

rmance $6.2B+ Revenue in FY25 Presence in 100+ countries #1 Pharma company in India by revenue 20% of Revenue from fast growing Innovative Medicines business Strong Balance Sheet with $3.1B+ Cas

14.4%

Global rights for Cequa In-licensed Winlevi® FY10 Rev: $823 Mn EBITDA: $287 Mn Revenue CAGR of 14.4% (FY10-25) EBIDTA CAGR of 13% (FY10-25) FY25 Rev: $6.2 Bn EBITDA: $1.8 Bn 6 Organon & Co: Stron

13%

censed Winlevi® FY10 Rev: $823 Mn EBITDA: $287 Mn Revenue CAGR of 14.4% (FY10-25) EBIDTA CAGR of 13% (FY10-25) FY25 Rev: $6.2 Bn EBITDA: $1.8 Bn 6 Organon & Co: Strong brand equity and global comm

30%

ies to manufacture complex products 5 Strong EBITDA and cashflows Stable adj. EBITDA margins of 30%+ over last 5 years • • Generating $1Bn+ free cashflows before financing 6 100 years of legacy

33%

s Top 5 established products player Biosimilars Top 10 global biosimilars platform 22 Products ~33%* Rev. contribution 50+ Products ~55%* Rev. contribution 8 Products ~11%* Rev. contribution *~1%

55%

Biosimilars Top 10 global biosimilars platform 22 Products ~33%* Rev. contribution 50+ Products ~55%* Rev. contribution 8 Products ~11%* Rev. contribution *~1% of revenue from other sources 8 Orga

11%

rs platform 22 Products ~33%* Rev. contribution 50+ Products ~55%* Rev. contribution 8 Products ~11%* Rev. contribution *~1% of revenue from other sources 8 Organon has a leading position in the hi

1%

33%* Rev. contribution 50+ Products ~55%* Rev. contribution 8 Products ~11%* Rev. contribution *~1% of revenue from other sources 8 Organon has a leading position in the high-potential Women’s Hea

10%

anon has a strong platform in WH to drive sustained growth $35Bn1+ total market size growing at 6-10% CAGR Several unmet needs across WH indications Less complex market access environment 100+ ass

15%

similars Market Organon Biosimilar Revenue: 13%+ CAGR over L5Y 1 2 3 $20+ Bn market growing at 15%+ 424 481 Revenue (USD Mn) 593 662 691 $320+ Bn cumulative peak sales of patented drugs reac

27%

ined entity Dermatology Women’s Health and other Innovation Ophthalmology Onco-Derma • • • 27% revenue share of combined business #3 position in Women’s Health (Contraception and Fertility)

Acquisition financed with

1

Acquisition financed with

• $2-2.5Bn of cash on hand • Balance $9.25-9.75 Bn to be funded through committed financing from banks 05 Subject to approval by Organon shareholders and customary regulatory approvals The transaction is expected to close in early 2027, subject to customary closing conditions *Adjusted for cash on books on 31st Dec, 2025 plus net proceeds from a product divestment 23 Next steps: Deal execution and integration planning for post-close Deal execution Integration planning for post-close 1 2 3 Submit regulatory filings Obtain Organon shareholder and relevant regulatory approvals Target closing, subject to customary approvals 1 2 3 4 Initiate integration planning including Integration Management Office Assess combined organizational capabilities and expertise Plan for cross cultural assimilation and ways of working Sustain momentum of existing businesses 24 Building our shared Culture Sunology The Organon Way Humility Integrity Passion Innovation Be Real We All Belong Bring Your Fire Own It